ArticleMetabolomics : Official journal of the Metabolomic Society2025
Metabolites and MRI-derived markers of dementia risk in a Puerto Rican cohort.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of infrared moxibustion for patients with mild hyperlipidemia: a protocol for a randomized controlled trial.Annals of medicine · 2026Article
- The interplay of air pollution with plasma neurodegenerative markers and metabolome for dementia, Parkinson's disease and all-cause mortality risks and transitions: The UK Biobank study.Ecotoxicology and environmental safety · 2026Article
- Review
- Atlas of plasma metabolic markers linked to human brain morphology.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
objectiveMetabolomic risk factors for dementia are under studied, especially in Latinos. We examined the relationship between plasma metabolomic profiles and a Magnetic-Resonance Imaging (MRI)-based markers of brain aging in a cohort of older adult Puerto Ricans residing in the greater Boston area.
methodsWe used multiple linear regression, adjusted for covariates, to examine the association between metabolite concentration and MRI-derived brain age deviation. Metabolites were measured at baseline with untargeted metabolomic profiling (Metabolon, Inc). Brain age deviation was calculated at wave 4 (~ 9 years from Boston Puerto Rican Health Study (BPRHS) baseline) as chronologic age, minus MRI-estimated brain age, representing the rate of biological brain aging relative to chronologic age. We also examined if metabolites associated with brain age deviation were similarly associated with hippocampal volume and global cognitive function.
resultsSeveral metabolites, including isobutyrylcarnitine, propionylcarnitine, phenylacetylglutamine, phenylacetylcarnitine (acetylated peptides), p-cresol-glucuronide, phenylacetylglutamate, and trimethylamine N-oxide (TMAO) were associated with worse brain aging. Taurocholate sulfate, a bile salt, was marginally associated with better brain aging. Most metabolites with negative associations with brain age deviation also were inversely, although not significantly, associated with hippocampal volume and cognitive function.
conclusionThe metabolites associated with brain aging in this study are generally consistent with prior literature and highlight the potential role of TMAO, BCAA and other microbially derived metabolites in dementia.
Indexed as
Identifiers
41233603What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.